Antibody-drug conjugates for targeting CD56-positive tumors

US10548987B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• THE CHILDREN'S HOSPITAL OF PHILADELPHIA · US

Inventors

• Dimiter S. Dimitrov · Frederick, US
• Yang Feng · Frederick, US
• John Maris · Philadelphia, US
• Zhongyu Zhu · Frederick, US
• Robyn Tovah Sussman · Philadelphia, US

Key dates

• Filing date: Jul 29, 2016
• Grant date: Feb 4, 2020
• Expiry date: Oct 25, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The identification and characterization of two fully human CD56-specific monoclonal antibodies targeting spatially separated epitopes proximal and distal to the plasma membrane is described. Also described are antibody-drug conjugates (ADCs) of the identified antibodies and their use for targeting CD56-expressing tumor cells.